Amphastar on Tuesday received a complete response letter from the agency, which identified issues with a study assessing how humans interact with the device and device evaluation, among other concerns.
The drugmaker, which currently sells naloxone in pre-filled syringes, must address these issues with the nasal spray before resubmitting an application for FDA approval.
More articles on opioids:
Ohio couple criminally charged after 8-year-old son’s apparent heroin overdose
Nearly 70% of opioids not safely stored in households with children
Could medical marijuana help remedy the opioid epidemic?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
